A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Individually Titrated Oral Doses of Runcaciguat in Subjects With Clinical Diagnosis of Chronic Kidney Disease With Diabetes and/or Hypertension and at Least One Cardiovascular Comorbidity
Latest Information Update: 15 Sep 2023
At a glance
- Drugs Runcaciguat (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Acronyms CONCORD
- Sponsors Bayer
Most Recent Events
- 14 Apr 2022 Status changed from active, no longer recruiting to completed.
- 10 Apr 2022 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 25 Feb 2022 This trial has been completed in Finland, according to European Clinical Trials Database record.